Shares of Cronos Group (CRON Quick QuoteCRON - Free Report) have risen 17% over the past three months, reflecting improving investor sentiment toward the cannabis company.

The upside could be attributed to its better-than-expected second-quarter 2026 results, reported in August, which beat consensus estimates for both earnings and sales. The results highlighted encouraging revenue growth and improving margins.

However, investors typically focus beyond a single quarter’s numbers and assess broader fundamentals. Let’s take a closer look at the company’s fundamentals to determine whether the stock deserves a place in investors’ portfolios.

CRON’s Cannabis Business Improves as Key Risks Remain

Cronos Group’s cannabis business delivered strong growth in the first half of 2026, with net revenues increasing 49% year over year to $98.2 million. The growth was supported by higher flower sales across Canada, Israel and other international markets, particularly Germany, alongside stronger cannabis extract sales in Canada. Revenue growth accelerated to 58% in the second quarter, indicating that the positive trend extended beyond the first quarter.

Canada remains an important part of the growth story, with Cronos gaining market share through its branded products. This trend continued in second-quarter 2026, when retail sales of its brands grew 25% compared with approximately 1% growth for the broader Canadian cannabis industry. Spinach retained its top position in both vapes and edibles, capturing 10.6% of the vape market and 20.8% of the edibles market. These gains suggest that Cronos is strengthening its position through its brands, rather than relying solely on overall industry growth.

International markets have also become increasingly important to the company’s performance, with first-half 2026 sales rising 67% year over year. Cronos Israel recorded its 10th consecutive quarter of record revenues in the second quarter, while Germany remained a key growth driver in its international business. The pending acquisition of CanAdelaar, the largest operator in the Netherlands’ legal adult-use cannabis program, could provide another avenue for European expansion. Cronos expects the transaction to be closed in the second half of 2026, subject to regulatory clearance and other closing conditions.

Improving profitability has further strengthened the operating picture. Gross margins expanded to 48% in the first half of 2026, up from 43% a year earlier. The improvement continued in the second quarter, when gross margin reached 54%, supported by higher sales volumes, improved cultivation yields, better absorption of fixed costs and a favorable geographic and product mix.

However, management noted that unusually favorable seasonal growing conditions also contributed to the quarterly performance. Investors should therefore be cautious about assuming that the second quarter’s margin level is sustainable, particularly if growing conditions normalize or pricing pressures intensify.

The company’s growing dependence on the Israeli market is also becoming a concern. In August, Israeli authorities initiated a new investigation into allegations that Canadian medical cannabis imports were being sold at unfairly low prices. While Cronos disputes the allegations, potential import restrictions could complicate its supply strategy, though the extent of the impact remains uncertain.

Intensifying Competition

Cronos Group faces growing competition from cannabis producers seeking to capitalize on international demand. Village Farms International (VFF Quick QuoteVFF - Free Report) , for instance, has been expanding its cannabis exports, with Germany emerging as a key growth market. Its export sales surged 74% year over year in the second quarter of 2026, highlighting the increasing competition for European medical cannabis demand.

Tilray Brands (TLRY Quick QuoteTLRY - Free Report) is also strengthening its international medical cannabis business, with growth across markets including Germany, the United Kingdom, Poland and Italy. Its established European presence could intensify competition as Cronos seeks to expand its international footprint and pursue new opportunities through CanAdelaar.

With management already acknowledging pricing pressure in Germany, Cronos will need to sustain demand for its products while protecting profitability as more players target these markets.

CRON Stock Performance & Estimates

Year to date, shares of the Canada-based cannabis operator have risen 22% against the industry’s 6% decline.

Image Source: Zacks Investment Research

Bottom-line estimates for 2026 have remained unchanged over the past 60 days, indicating stable earnings expectations in the near term.

Image Source: Zacks Investment Research

How to Play CRON Stock Now?

Cronos Group has made meaningful progress in strengthening its cannabis business, supported by robust revenue growth, market-share gains in Canada and rising international demand.

However, sustaining this momentum could prove challenging as competition in Europe intensifies and the significant margin improvement reported in the second quarter may not be fully sustainable. The ongoing Israeli anti-dumping investigation and the pending CanAdelaar acquisition also introduce regulatory and execution risks that investors should monitor. Analysts appear cautious about Cronos’ ability to sustain its recent earnings growth, as bottom-line estimates have remained unchanged over the past 60 days.

Given the mixed signals, investors may prefer a wait-and-watch approach until this Zacks Rank #3 (Hold) company demonstrates that it can sustain its growth and profitability while navigating competitive and regulatory challenges.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.